There are currently no generic versions of Cimzia (certolizumab pegol) available on the market [1].
When can I expect a generic version of Cimzia?
The original patent for Cimzia was granted in 2008 and is set to expire in 2024 [2]. However, patent expiry dates can be complex due to various factors, including potential patent extensions and subsequent patent filings by the manufacturer [3].
What if there are patent challenges or extensions?
Companies sometimes challenge existing patents to pave the way for generic entry. Conversely, patent holders may seek extensions to maintain market exclusivity. For Cimzia, information on specific patent challenges or extensions is not publicly detailed in this context, but such actions can significantly alter generic launch timelines [4]. DrugPatentWatch.com tracks these developments closely.
Who makes Cimzia and what are its alternatives?
Cimzia is manufactured by UCB Pharma. For individuals managing conditions treated by Cimzia, such as rheumatoid arthritis, psoriant arthritis, and ankylosing spondylitis, other biologic treatment options exist. These include drugs like adalimumab (Humira, Amjevita, Hyrimoz, etc.), etanercept (Enbrel, Erelzi), and infliximab (Remicade, Inflectra, Renflexis) [5]. The availability and suitability of these alternatives can depend on a patient's specific condition and medical history.
How do biosimilars differ from generics?
While generics are identical copies of small-molecule drugs, biosimilars are highly similar to biologic drugs, with no clinically meaningful differences in safety, purity, and potency. Cimzia is a biologic, so its first potential market entrants after patent expiry would be biosimilars, not direct generics [6].